Exclusion Criteria:~1. Any significant neurologic disease including Parkinson's disease, stroke, multiinfarct
dementia, frontotemporal dementia, Lewy body dementia, normal pressure hydrocephalus, brain tumor, brain
hemorrhage with persistent neurologic deficits, progressive supra-nuclear palsy, seizure disorder, multiple
sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural
brain abnormalities.~2. Clinically significant or unstable medical conditions, including uncontrolled
hypertension, uncontrolled diabetes, or significant cardiac, pulmonary, renal, hepatic, endocrine, or other
systemic diseases.~3. History of autoimmune disease.~4. Current treatment with immunomodulatory or
immunosuppressive drugs or corticosteroid administration by any route of administration (including nasal
corticosteroids) within the past month.~5. Major depressive disorder (within the past 1 year), or a history of
bipolar disorder, or a history of schizophrenia.~6. History of alcohol or substance abuse or dependence within
the past two years.~7. History of malignancy within the past 3 years.~8. Clinically significant abnormalities
in screening laboratories (defined as greater than mild on the FDA's vaccine toxicity grading scale).~9.
Participation in another clinical trial of an investigational drug concurrently or within the past 30 days.~10.
Low affinity TSPO binders (for PET ligand \[18F\]PBR06) determined by having a Thr/Thr polymorphism in the TSPO
gene at screening.~11. Sensitivity to florbetapir F18.~12. Active COVID-19 disease.~13. Amyloid-negative PET
scan.~14. COVID-19 vaccine within the past ten days or any other vaccine within the past seven days (at dosing)
